To the Editor In their recent article 鈥淐ost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US,鈥� Ross et al1 provide much needed insights into an important question given the potentially large treatment-eligible population and the expected budget impact of an Alzheimer treatment. However, their analysis has several methodologic flaws that may lead them to understate the value of such treatments.